Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $398,850.00 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction on Monday, December 29th. The stock was sold at an average price of $26.59, for a total transaction of $398,850.00. Following the sale, the insider owned 409,786 shares of the company’s stock, valued at $10,896,209.74. The trade was a 3.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Kestra Medical Technologies Stock Performance

Shares of KMTS traded down $0.45 during trading hours on Wednesday, reaching $26.52. 489,936 shares of the company traded hands, compared to its average volume of 289,819. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.26. The business has a fifty day moving average price of $26.29 and a 200-day moving average price of $21.37. Kestra Medical Technologies, Ltd. has a 12-month low of $13.25 and a 12-month high of $30.00. The stock has a market capitalization of $1.55 billion and a P/E ratio of -8.37.

Hedge Funds Weigh In On Kestra Medical Technologies

Several large investors have recently made changes to their positions in the company. Yu Fan purchased a new stake in Kestra Medical Technologies during the first quarter worth $56,880,000. Alliancebernstein L.P. raised its holdings in shares of Kestra Medical Technologies by 13.7% during the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock valued at $35,449,000 after acquiring an additional 179,885 shares during the last quarter. Eventide Asset Management LLC boosted its stake in Kestra Medical Technologies by 285.7% during the 2nd quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company’s stock worth $17,584,000 after purchasing an additional 785,557 shares during the last quarter. Brown Advisory Inc. boosted its position in Kestra Medical Technologies by 5.4% during the second quarter. Brown Advisory Inc. now owns 580,025 shares of the company’s stock worth $9,617,000 after acquiring an additional 29,607 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Kestra Medical Technologies in the first quarter valued at approximately $11,036,000.

Wall Street Analyst Weigh In

KMTS has been the subject of a number of research reports. Piper Sandler lifted their target price on Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kestra Medical Technologies in a report on Wednesday, December 24th. Wall Street Zen lowered shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Sunday, September 28th. The Goldman Sachs Group boosted their target price on shares of Kestra Medical Technologies from $22.00 to $25.00 and gave the company a “neutral” rating in a research report on Saturday, December 13th. Finally, BTIG Research initiated coverage on shares of Kestra Medical Technologies in a report on Tuesday, November 18th. They issued a “buy” rating and a $32.00 price target on the stock. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Kestra Medical Technologies currently has an average rating of “Moderate Buy” and a consensus target price of $29.14.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.